SG143042A1 - Treatment for diabetes - Google Patents
Treatment for diabetesInfo
- Publication number
- SG143042A1 SG143042A1 SG200402994-8A SG2004029948A SG143042A1 SG 143042 A1 SG143042 A1 SG 143042A1 SG 2004029948 A SG2004029948 A SG 2004029948A SG 143042 A1 SG143042 A1 SG 143042A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- diabetes
- kit
- ingredient
- patient
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
- 102000052874 Gastrin receptors Human genes 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/241,100 US6558952B1 (en) | 1992-12-14 | 1999-01-29 | Treatment for diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG143042A1 true SG143042A1 (en) | 2008-06-27 |
Family
ID=22909247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200402994-8A SG143042A1 (en) | 1999-01-29 | 1999-10-27 | Treatment for diabetes |
Country Status (11)
Country | Link |
---|---|
US (4) | US6558952B1 (xx) |
EP (1) | EP1071447A1 (xx) |
JP (2) | JP2004506591A (xx) |
KR (2) | KR20050096212A (xx) |
CN (2) | CN101524530A (xx) |
AU (2) | AU774746B2 (xx) |
CA (1) | CA2326741A1 (xx) |
IL (1) | IL138784A0 (xx) |
SE (1) | SE0003508L (xx) |
SG (1) | SG143042A1 (xx) |
WO (1) | WO2000044400A1 (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
US20020099008A1 (en) | 1999-04-26 | 2002-07-25 | Daniel R. Twardzik | Method for stimulating hematopoiesis using tgf-alpha |
JP2002543096A (ja) | 1999-04-26 | 2002-12-17 | ステム セル ファーマシューティカルズ,インコーポレーテッド | TGF−αポリペプチド、機能性断片およびそれらの利用法 |
US6677307B2 (en) | 1999-08-19 | 2004-01-13 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
AU6920800A (en) * | 1999-08-19 | 2001-03-13 | Stem Cell Pharmaceuticals, Inc. | Tgf-alpha polypeptides, functional fragments and methods of use therefor |
US6815418B2 (en) | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
WO2002055152A2 (en) | 2001-01-12 | 2002-07-18 | Waratah Pharmaceuticals, Inc. | Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
WO2003068357A2 (en) * | 2002-02-12 | 2003-08-21 | Cornell Research Foundation, Inc. | Identification and high-yield isolation of human pancreatic islet progenitor and stem cells |
IL165242A0 (en) * | 2002-05-24 | 2005-12-18 | Waratah Pharmaceuticals Inc | Treatment for diabetes |
EP1511509B1 (en) * | 2002-06-07 | 2007-10-10 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病の処置 |
US7025791B2 (en) | 2002-12-02 | 2006-04-11 | Gi Dynamics, Inc. | Bariatric sleeve |
EP1620464A1 (en) * | 2003-04-30 | 2006-02-01 | Waratah Pharmaceuticals, Inc. | Combined use of keratinocyte growth factor agonists and gastrin compounds |
RU2005140518A (ru) * | 2003-05-27 | 2007-07-10 | Уэйрейта Фармасьютиклз, Инк. (Ca) | Композиции и способы, включающие соединения гастрина |
US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
EP1631822A2 (en) * | 2003-05-27 | 2006-03-08 | McGILL UNIVERSITY | "in vitro" platform for screening agents inducing islet cell neogenesis |
US20090202494A1 (en) * | 2004-01-30 | 2009-08-13 | Antonio Cruz | Combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
CA2571957A1 (en) * | 2004-07-01 | 2006-01-12 | Waratah Pharmaceuticals, Inc. | Methods and compositions using cd3 agonists |
AU2006279680B2 (en) * | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
EP1951286A4 (en) * | 2005-10-07 | 2009-11-04 | Waratah Pharmaceuticals Inc | COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS |
US8093038B2 (en) * | 2007-09-17 | 2012-01-10 | Illinois Institute Of Technology | Apparatus and method for encapsulating pancreatic cells |
WO2010002492A1 (en) * | 2008-04-29 | 2010-01-07 | University Of Chicago | Methods of use of adenine derivatives for the treatment of diabetes and other disorders |
JP5838557B2 (ja) | 2010-07-05 | 2016-01-06 | ソニー株式会社 | 生体情報処理方法および装置、並びに記録媒体 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464363A (en) * | 1979-12-20 | 1984-08-07 | Merck & Co., Inc. | Ajuvants for rectal delivery of drug substances |
EP0239716B1 (en) * | 1986-01-10 | 1993-03-31 | Alfio Bertolini | Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies |
WO1995019785A1 (en) * | 1994-01-24 | 1995-07-27 | Research Triangle Pharmaceuticals Ltd. | Treatment for juvenile diabetes |
WO1996011701A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Enteric coated compositions of 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity |
WO1997025030A1 (en) * | 1996-01-08 | 1997-07-17 | Astra Aktiebolag | Multiple unit effervescent dosage forms comprising protonpump inhibitor |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE38892B1 (en) * | 1973-03-28 | 1978-06-21 | Ici Ltd | Pharmaceutical compositions |
JPS6028994A (ja) * | 1983-07-08 | 1985-02-14 | Wakunaga Seiyaku Kk | 〔21―ロイシン〕ヒトウロガストロン |
US4686283A (en) * | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
EP0284898A3 (de) * | 1987-04-02 | 1990-06-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene |
US5102789A (en) * | 1989-03-15 | 1992-04-07 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Production of epideramal growth factor in pichia pastoris yeast cells |
US5023077A (en) * | 1989-01-24 | 1991-06-11 | Aphton Corporation | Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease |
US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
US5158935A (en) * | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
US5434135A (en) * | 1990-08-02 | 1995-07-18 | Indu Parikh | Growth factor compositions, preparation and use |
WO1992002246A1 (en) * | 1990-08-02 | 1992-02-20 | Indu Parikh | Growth factor compositions, preparation and use |
US5468727A (en) * | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
US5187154A (en) * | 1990-12-13 | 1993-02-16 | Board Of Regents, The University Of Texas System | Diagnosis and treatment of humans with diabetes or at risk to develop diabetes |
WO1992021029A1 (en) * | 1991-05-10 | 1992-11-26 | Genentech, Inc. | Selecting ligand agonists and antagonists |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5290920A (en) * | 1992-04-16 | 1994-03-01 | Allelix Biopharmaceuticals Inc. | Method of purifying human epidermal growth factor |
US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5624895A (en) * | 1994-02-18 | 1997-04-29 | Georgetown University Medical Center | Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration |
US5587309A (en) * | 1994-04-29 | 1996-12-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo |
WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US6346390B1 (en) * | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
JP2001521897A (ja) * | 1997-10-31 | 2001-11-13 | スミスクライン・ビーチャム・コーポレイション | 新規な金属錯体 |
CA2312190A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
EP1932535A3 (en) * | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
US6242666B1 (en) * | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
JP2002538779A (ja) * | 1999-02-10 | 2002-11-19 | キュリス インコーポレイテッド | 膵臓細胞前駆細胞、それらに関する方法及び利用 |
US6815203B1 (en) * | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
US6866843B2 (en) * | 1999-12-06 | 2005-03-15 | Viacell, Inc. | Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell |
CA2400355A1 (en) * | 2000-02-18 | 2001-08-23 | The Walter And Eliza Hall Institute Of Medical Research | Pancreatic islet cell growth factors |
WO2002055152A2 (en) * | 2001-01-12 | 2002-07-18 | Waratah Pharmaceuticals, Inc. | Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
CA2442177A1 (en) * | 2001-03-29 | 2002-10-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
EP1401282A4 (en) * | 2001-05-25 | 2005-03-30 | Cythera Inc | DIFFERENTIATION OF STEM CELLS |
JP5562510B2 (ja) * | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー/エス | 修飾glp−1の安定な処方剤 |
US20030049236A1 (en) * | 2001-07-27 | 2003-03-13 | Arhus Amt | Immortalized stem cells |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
JP4666567B2 (ja) * | 2001-12-07 | 2011-04-06 | ジェロン・コーポレーション | ヒト胚幹細胞由来の膵島細胞 |
IL165242A0 (en) * | 2002-05-24 | 2005-12-18 | Waratah Pharmaceuticals Inc | Treatment for diabetes |
EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
EP1511509B1 (en) * | 2002-06-07 | 2007-10-10 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病の処置 |
-
1999
- 1999-01-29 US US09/241,100 patent/US6558952B1/en not_active Expired - Fee Related
- 1999-10-27 IL IL13878499A patent/IL138784A0/xx unknown
- 1999-10-27 KR KR1020057017993A patent/KR20050096212A/ko not_active Application Discontinuation
- 1999-10-27 KR KR1020007010902A patent/KR20010074466A/ko not_active Application Discontinuation
- 1999-10-27 CN CNA2009101287169A patent/CN101524530A/zh active Pending
- 1999-10-27 CN CNB998067776A patent/CN100482686C/zh not_active Expired - Fee Related
- 1999-10-27 JP JP2000595702A patent/JP2004506591A/ja active Pending
- 1999-10-27 SG SG200402994-8A patent/SG143042A1/en unknown
- 1999-10-27 AU AU13319/00A patent/AU774746B2/en not_active Ceased
- 1999-10-27 WO PCT/US1999/025463 patent/WO2000044400A1/en not_active Application Discontinuation
- 1999-10-27 CA CA002326741A patent/CA2326741A1/en not_active Abandoned
- 1999-10-27 EP EP99956786A patent/EP1071447A1/en not_active Withdrawn
-
2000
- 2000-09-29 SE SE0003508A patent/SE0003508L/xx not_active Application Discontinuation
-
2001
- 2001-12-20 US US10/029,551 patent/US20020081285A1/en not_active Abandoned
-
2004
- 2004-05-11 US US10/843,780 patent/US20040209816A1/en not_active Abandoned
- 2004-10-08 AU AU2004218687A patent/AU2004218687B2/en not_active Ceased
-
2008
- 2008-01-04 JP JP2008000115A patent/JP2008094854A/ja active Pending
- 2008-06-10 US US12/136,422 patent/US20090041731A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464363A (en) * | 1979-12-20 | 1984-08-07 | Merck & Co., Inc. | Ajuvants for rectal delivery of drug substances |
EP0239716B1 (en) * | 1986-01-10 | 1993-03-31 | Alfio Bertolini | Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies |
WO1995019785A1 (en) * | 1994-01-24 | 1995-07-27 | Research Triangle Pharmaceuticals Ltd. | Treatment for juvenile diabetes |
WO1996011701A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Enteric coated compositions of 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity |
WO1997025030A1 (en) * | 1996-01-08 | 1997-07-17 | Astra Aktiebolag | Multiple unit effervescent dosage forms comprising protonpump inhibitor |
Non-Patent Citations (2)
Title |
---|
FUNCTION AND REGULATION OF GASTRIN IN TRANSGENIC MICE: A REVIEW * |
PANCREATIC GASTRIN STIMULATES ISLET DIFFERENTIATION OF TRANSFORM * |
Also Published As
Publication number | Publication date |
---|---|
AU2004218687B2 (en) | 2008-02-21 |
JP2004506591A (ja) | 2004-03-04 |
KR20010074466A (ko) | 2001-08-04 |
US20020081285A1 (en) | 2002-06-27 |
CN100482686C (zh) | 2009-04-29 |
KR20050096212A (ko) | 2005-10-05 |
EP1071447A1 (en) | 2001-01-31 |
JP2008094854A (ja) | 2008-04-24 |
AU1331900A (en) | 2000-08-18 |
SE0003508D0 (sv) | 2000-09-29 |
US6558952B1 (en) | 2003-05-06 |
CN1308544A (zh) | 2001-08-15 |
CN101524530A (zh) | 2009-09-09 |
AU2004218687A1 (en) | 2004-11-04 |
US20040209816A1 (en) | 2004-10-21 |
SE0003508L (sv) | 2000-11-21 |
CA2326741A1 (en) | 2000-08-03 |
US20090041731A1 (en) | 2009-02-12 |
AU774746B2 (en) | 2004-07-08 |
WO2000044400A1 (en) | 2000-08-03 |
IL138784A0 (en) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG143042A1 (en) | Treatment for diabetes | |
HK1031201A1 (en) | Mixing/charging port for medical treatment. | |
HK1048428A1 (en) | Ophthalmic drug delivery device. | |
IL138990A0 (en) | Matrices for drug delivery and methods for making and using the same | |
IL151202A0 (en) | Phenyl derivatives, a process for their praparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy | |
HUP0002628A2 (en) | Pharmaceutical combinations for treating diabetes | |
EP1194173A4 (en) | ADMINISTRATION OF MEDICINE GUIDED BY X-RAY | |
HK1044769A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof. | |
ZA991520B (en) | Container for a medical liquid. | |
IL144728A0 (en) | Iontophoresis, electroporation and combination patches for local drug delivery | |
MY125978A (en) | Admantane derivatives | |
PT1242055E (pt) | Forma de dosagem de fármaco baseada em hidrogel | |
HK1040679A1 (zh) | 裝兩種分開的、不穩定物質的藥物容器 | |
HK1033278A1 (en) | Pharmaceutical preparation for use in anti-asthma therapy. | |
GB2314022B (en) | Blending medical composition with sustained medicament releasability and process for preparing the same | |
AU4612300A (en) | Preventive or therapeutic drugs for diabetes | |
ZA972147B (en) | Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients. | |
HUP0201047A3 (en) | Steroid compounds with a c17-alkyl side chain and an aromatic a-ring, process for their preparation and pharmaceutical compositions containing the compounds | |
ZA97976B (en) | Uniform drug delivery theraphy. | |
HUP0301333A2 (hu) | Gyógyszer szuperdezintegráns, eljárás az előállítására és alkalmazása | |
HUP0103852A3 (en) | Container for intravenous administration | |
HK1044725A1 (en) | Mixing/charging port for medical treatment. | |
ZA200000171B (en) | Analgesic with controlled active substance release. | |
ZA974665B (en) | Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. | |
ZA989781B (en) | Novel bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them. |